Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / FundiShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerBTEC(USD) LSE
ETF TickerBTEK(GBP) LSE
ETF Ticker2B70(EUR) F
ETF Ticker2B70.DE(EUR) CXE
ETF TickerBTEC.LS(USD) CXE
ETF TickerBTEK.LS(GBP) CXE
ETF TickerBTEC.L(GBP) LSE
ETF TickerBTEK.L(GBP) LSE

Holdings detail for ALNY

Stock NameAlnylam Pharmaceuticals Inc
TickerALNY(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS02043Q1076
LEI529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by Royal Bank Of Canada from $435.00 to $500.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ALNY has been the topic of several other reports. The Goldman Sachs Group boosted their price […] - 2025-09-22 02:32:43
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $520.00 Price Target at Bank of America
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective raised by Bank of America from $453.00 to $520.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other equities analysts have also weighed in on ALNY. Oppenheimer upgraded shares […] - 2025-09-18 04:26:54
The Goldman Sachs Group Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its target price increased by The Goldman Sachs Group from $504.00 to $566.00 in a report published on Tuesday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also commented on the stock. Chardan Capital lifted […] - 2025-09-17 03:14:44
Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $421.28
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twenty-seven analysts that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1 year target price […] - 2025-09-15 02:47:58
Alnylam Announces Pricing Of Upsized Offering Of $575 Mln Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced the pricing of its private offering of $575 million aggregate principal amount of 0.00% convertible senior notes due 2028. The size of the offering was increased from the previously announced offering of $500 million aggre - 2025-09-10 00:33:28
Alnylam Pharma Commences Private Offering Of $500 Mln Of Convertible Senior Notes Due 2028
(RTTNews) - Alnylam Pharmaceuticals Inc. (ALNY) announced that it has commenced a private offering of $500 million aggregate principal amount of convertible senior notes due 2028. In connection with this offering, Alnylam expects to grant the initial purchasers of the notes an op - 2025-09-09 00:30:30
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
Alnylam and Roche report positive phase II KARDIA-3 results for zilebesiran in high-risk hypertension patients, fueling momentum for a phase III study. - 2025-09-01 11:50:00
Notable ETF Outflow Detected - XBI, ALNY, HALO, INSM
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $119.6 million dollar outflow -- that's a 2.2% decrease week over week - 2025-08-28 11:56:11
Dennis A. Ausiello Sells 31,448 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Dennis A. Ausiello sold 31,448 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in […] - 2025-08-18 05:14:55
LPL Financial LLC Buys 2,107 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
LPL Financial LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 11.3% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 20,679 shares of the biopharmaceutical company’s stock after acquiring an additional 2,107 shares during the period. LPL Financial LLC’s holdings […] - 2025-08-13 05:04:56
XBI, ALNY, INSM, INCY: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $202.3 million dollar outflow -- that's a 4.3% decrease week over week - 2025-08-12 11:55:54
Cetera Investment Advisers Has $2.17 Million Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Cetera Investment Advisers raised its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 68.1% during the first quarter, Holdings Channel reports. The firm owned 8,017 shares of the biopharmaceutical company’s stock after purchasing an additional 3,247 shares during the period. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $2,165,000 at the end […] - 2025-08-08 04:44:59
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at Oppenheimer
Oppenheimer upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a market perform rating to an outperform rating in a research report sent to investors on Monday, Marketbeat.com reports. The brokerage currently has $490.00 target price on the biopharmaceutical company’s stock. ALNY has been the subject of several other reports. Barclays lifted their price […] - 2025-08-07 02:54:47
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by Wolfe Research to Peer Perform Rating
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by equities research analysts at Wolfe Research from an “underperform” rating to a “peer perform” rating in a research report issued on Monday, Marketbeat reports. A number of other brokerages have also recently issued reports on ALNY. Canaccord Genuity Group lifted their price target on shares […] - 2025-08-06 03:02:54
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $400.00 at Chardan Capital
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price objective lifted by Chardan Capital from $325.00 to $400.00 in a research report report published on Friday,Benzinga reports. Chardan Capital currently has a buy rating on the biopharmaceutical company’s stock. Several other research analysts have also issued reports on ALNY. Needham & Company LLC raised their […] - 2025-08-04 02:48:47
Needham & Company LLC Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $478.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target hoisted by Needham & Company LLC from $377.00 to $478.00 in a research report report published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the biopharmaceutical company’s stock. A number of other research analysts also recently commented on the […] - 2025-08-03 05:28:56
Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 11:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 06:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 05:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 06:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial
Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 03:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 05:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 05:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.
Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 04:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 04:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 03:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 07:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 05:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 02:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 06:20:52

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ALNY holdings

DateNumber of ALNY Shares HeldBase Market Value of ALNY SharesLocal Market Value of ALNY SharesChange in ALNY Shares HeldChange in ALNY Base ValueCurrent Price per ALNY Share HeldPrevious Price per ALNY Share Held
2025-11-12 (Wednesday)84,466ALNY holding increased by 216USD 38,241,137ALNY holding increased by 164349USD 38,241,137216USD 164,349 USD 452.74 USD 451.95
2025-11-11 (Tuesday)84,250USD 38,076,788ALNY holding increased by 863563USD 38,076,7880USD 863,563 USD 451.95 USD 441.7
2025-11-10 (Monday)84,250ALNY holding increased by 215USD 37,213,225ALNY holding increased by 10930USD 37,213,225215USD 10,930 USD 441.7 USD 442.7
2025-11-07 (Friday)84,035USD 37,202,295ALNY holding increased by 185718USD 37,202,2950USD 185,718 USD 442.7 USD 440.49
2025-11-06 (Thursday)84,035ALNY holding increased by 215USD 37,016,577ALNY holding increased by 591758USD 37,016,577215USD 591,758 USD 440.49 USD 434.56
2025-11-05 (Wednesday)83,820USD 36,424,819ALNY holding increased by 929564USD 36,424,8190USD 929,564 USD 434.56 USD 423.47
2025-11-04 (Tuesday)83,820ALNY holding increased by 216USD 35,495,255ALNY holding decreased by -794733USD 35,495,255216USD -794,733 USD 423.47 USD 434.07
2025-11-03 (Monday)83,604USD 36,289,988ALNY holding decreased by -1836780USD 36,289,9880USD -1,836,780 USD 434.07 USD 456.04
2025-10-31 (Friday)83,604USD 38,126,768ALNY holding increased by 541754USD 38,126,7680USD 541,754 USD 456.04 USD 449.56
2025-10-30 (Thursday)83,604ALNY holding increased by 1080USD 37,585,014ALNY holding decreased by -2157719USD 37,585,0141,080USD -2,157,719 USD 449.56 USD 481.59
2025-10-29 (Wednesday)82,524ALNY holding increased by 621USD 39,742,733ALNY holding increased by 764276USD 39,742,733621USD 764,276 USD 481.59 USD 475.91
2025-10-28 (Tuesday)81,903USD 38,978,457ALNY holding decreased by -218681USD 38,978,4570USD -218,681 USD 475.91 USD 478.58
2025-10-27 (Monday)81,903USD 39,197,138ALNY holding increased by 1240831USD 39,197,1380USD 1,240,831 USD 478.58 USD 463.43
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BYXG2H39

Show aggregate share trades of ALNY

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12BUY216459.270447.130 448.344USD 96,842 312.97
2025-11-10BUY215449.680440.930 441.805USD 94,988 311.65
2025-11-06BUY215445.490429.000 430.649USD 92,590 310.37
2025-11-04BUY216431.500421.830 422.797USD 91,324 309.18
2025-10-30BUY1,080471.980436.512 440.059USD 475,263 307.09
2025-10-29BUY621481.590482.730 482.616USD 299,704 306.20
2025-10-22SELL-864464.900480.530 478.967USD -413,827 301.93 Loss of -152,962 on sale
2025-10-20BUY432491.220495.550 495.117USD 213,891 300.02
2025-10-17BUY1,079481.670492.620 491.525USD 530,355 299.05
2025-10-15BUY1,720470.270485.280 483.779USD 832,100 298.13
2025-10-03BUY1,498456.350465.010 464.144USD 695,288 296.35
2025-10-02BUY214460.990461.530 461.476USD 98,756 295.46
2025-09-30BUY428456.000459.300 458.970USD 196,439 293.67
2025-09-26BUY428446.400453.050 452.385USD 193,621 291.96
2025-09-25BUY428449.580459.000 458.058USD 196,049 291.08
2025-09-24BUY5,850458.370462.690 462.258USD 2,704,209 290.14
2025-09-18BUY196452.170456.940 456.463USD 89,467 289.23
2025-09-17BUY588451.730463.880 462.665USD 272,047 288.31
2025-09-11SELL-196468.580474.340 473.764USD -92,858 286.28 Loss of -36,748 on sale
2025-09-10BUY392469.310480.050 478.976USD 187,759 285.22
2025-09-05SELL-197452.000455.280 454.952USD -89,626 282.08 Loss of -34,056 on sale
2025-08-20SELL-784458.310466.310 465.510USD -364,960 278.93 Loss of -146,279 on sale
2025-08-18BUY392456.870457.920 457.815USD 179,463 276.76
2025-07-30BUY901339.800345.980 345.362USD 311,171 272.68
2025-07-17SELL-392324.690329.870 329.352USD -129,106 269.54 Loss of -23,448 on sale
2025-07-16BUY680322.810323.410 323.350USD 219,878 269.18
2025-07-11SELL-1,552314.940321.120 320.502USD -497,419 268.27 Loss of -81,067 on sale
2025-07-07BUY582324.130328.240 327.829USD 190,796 266.78
2025-07-02BUY10,670329.770330.000 329.977USD 3,520,855 265.88
2025-06-20SELL-6,084309.700314.500 314.020USD -1,910,498 265.56 Loss of -294,810 on sale
2025-06-13BUY121307.990308.020 308.017USD 37,270 263.92
2025-06-11BUY430298.580303.850 303.323USD 130,429 263.35
2025-06-10BUY430302.460308.890 308.247USD 132,546 263.05
2025-06-04SELL-215305.310308.930 308.568USD -66,342 261.76 Loss of -10,064 on sale
2025-04-23BUY215241.970248.590 247.928USD 53,305 257.63
2025-04-10SELL-1,720226.280235.330 234.425USD -403,211 260.05 Profit of 44,068 on sale
2025-04-08SELL-215224.320246.150 243.967USD -52,453 260.65 Profit of 3,587 on sale
2025-04-07SELL-215232.950241.830 240.942USD -51,803 260.97 Profit of 4,306 on sale
2025-04-04SELL-1,075235.740259.160 256.818USD -276,079 261.27 Profit of 4,784 on sale
2025-04-01BUY1,845255.760273.610 271.825USD 501,517 261.27
2025-03-31SELL-633270.020271.850 271.667USD -171,965 261.16 Loss of -6,650 on sale
2025-03-21BUY2,889283.340289.440 288.830USD 834,430 259.89
2025-03-14SELL-3,232241.760244.040 243.812USD -788,000 260.64 Profit of 54,385 on sale
2025-03-07SELL-404244.520251.120 250.460USD -101,186 262.20 Profit of 4,741 on sale
2025-03-04SELL-202242.930244.670 244.496USD -49,388 262.93 Profit of 3,724 on sale
2025-02-25BUY404245.200251.560 250.924USD 101,373 264.62
2025-02-19SELL-202250.510254.010 253.660USD -51,239 265.69 Profit of 2,429 on sale
2025-02-13BUY606264.890268.520 268.157USD 162,503 266.39
2025-02-12BUY202265.960268.200 267.976USD 54,131 266.39
2025-02-11BUY808268.990273.230 272.806USD 220,427 266.34
2025-01-02BUY102233.620239.990 239.353USD 24,414 263.76
2024-12-30SELL-6,947236.010236.950 236.856USD -1,645,439 264.60 Profit of 192,714 on sale
2024-11-18SELL-3,300232.270242.490 241.468USD -796,844 280.15 Profit of 127,640 on sale
2024-11-08SELL-220277.430279.510 279.302USD -61,446 281.14 Profit of 405 on sale
2024-10-30BUY117281.490287.870 287.232USD 33,606 290.50
2024-10-21SELL-220292.010295.390 295.052USD -64,911 0.00 Loss of -64,911 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19216,7273,259396,24354.7%
2025-09-18172,875397386,43244.7%
2025-09-17246,547167472,29252.2%
2025-09-1688,84660226,33639.3%
2025-09-15148,25813,572435,68934.0%
2025-09-12134,122300244,96854.8%
2025-09-11219,8687,820411,70253.4%
2025-09-10543,3267,595916,89859.3%
2025-09-09705,54033,7311,550,89945.5%
2025-09-08175,158440388,71545.1%
2025-09-05127,116335311,25240.8%
2025-09-04110,9302,555236,56846.9%
2025-09-03182,3868,982562,92132.4%
2025-09-02132,77014,416358,47637.0%
2025-08-2993,2162,181276,59433.7%
2025-08-2860,1821,254226,86526.5%
2025-08-27277,6671,084440,57763.0%
2025-08-26243,404919447,42154.4%
2025-08-25156,55115,662374,27641.8%
2025-08-22228,5961,309408,15256.0%
2025-08-21123,9962,862248,30049.9%
2025-08-20149,63813,723316,98347.2%
2025-08-19144,3201,143308,39946.8%
2025-08-18371,31834,264525,78670.6%
2025-08-15104,01813,245265,62039.2%
2025-08-14133,2724,443505,52826.4%
2025-08-13183,2711,3901,017,62318.0%
2025-08-12173,0454,046693,01825.0%
2025-08-11239,1997,600451,24853.0%
2025-08-08168,7553,199466,74436.2%
2025-08-07308,8104,452527,39958.6%
2025-08-06202,15112,590548,34936.9%
2025-08-05256,29513,237826,28331.0%
2025-08-04411,11436,303729,94956.3%
2025-08-01350,06060,108764,94345.8%
2025-07-31829,1916,0231,541,01553.8%
2025-07-30533,88514,703942,78856.6%
2025-07-29164,26855384,53742.7%
2025-07-28150,24069571,96526.3%
2025-07-2590,782429298,80130.4%
2025-07-24132,00111,546286,15546.1%
2025-07-23184,14963312,34059.0%
2025-07-22134,7617,553524,61225.7%
2025-07-21113,303101243,11946.6%
2025-07-1884,1179196,31742.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.